Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22350693 | 0.90 | SMN1; SMN2 (0.37) | SMN1; SMN2POLBCYP1A2TDP1 | |
| SCHEMBL20777959 | 0.84 | CYP4F2 (0.38) | SMN1; SMN2POLBCYP1A2TDP1ALDH1A1 | |
| SCHEMBL20804513 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBCYP1A2TDP1ALDH1A1 | |
| SCHEMBL20153143 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2POLBCYP1A2TDP1ALDH1A1 | |
| SCHEMBL14818665 | 0.78 | CYP1A2 (0.41) | SMN1; SMN2CYP1A2TDP1ALDH1A1PIK3CD | |
| SCHEMBL11832269 | 0.77 | ALDH1A1 (0.46) | SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL8303667 | 0.76 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBCYP1A2TDP1ALDH1A1 | |
| SCHEMBL22350683 | 0.71 | TDP1 (0.39) | CYP1A2TDP1ALDH1A1KDM4E | |
| SCHEMBL20738498 | 0.70 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP1A2TDP1ALDH1A1PIK3CD | |
| SCHEMBL25633506 | 0.70 | SMN1; SMN2 (0.45) | SMN1; SMN2POLBCYP1A2TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102583-A1 | CEPHEM COMPOUND HAVING CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2013-04-25 | — | — | US | disclosed |
| US-20130079319-A1 | CEPHEM COMPOUND HAVING PSEUDO-CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079319-A1 | CEPHEM COMPOUND HAVING PSEUDO-CATECHOL GROUP | CENPE, CCNE2, CEP170 | SMN1; SMN2 4554/4885POLB 1824/4885CYP1A2 1524/4885 |
| US-20130102583-A1 | CEPHEM COMPOUND HAVING CATECHOL GROUP | COMT, EZH1, SETD7 | SMN1; SMN2 4252/4885POLB 1918/4885CYP1A2 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.